₹38.87
▼ -0.09 -0.23%
17 Jul 2026
NSE Listed
Medico Remedies Limited (MEDICO)
20-day avg volume: 1.4L shares
- Revenue fell 38% YoY.
- Stock trades at a high P/E of 55.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹31 Cr | ₹39 Cr | ₹39 Cr | ₹41 Cr | ₹38 Cr | ₹53 Cr | ₹59 Cr | ₹57 Cr |
| EBITDA | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹6 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹9 Cr |
| Net Profit | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹6 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹62 Cr | ₹100 Cr | ₹91 Cr | ₹123 Cr | ₹123 Cr | ₹144 Cr | ₹147 Cr | ₹154 Cr |
| EBITDA | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹7 Cr | ₹11 Cr | ₹12 Cr | ₹15 Cr |
| Net Profit | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹5 Cr | ₹7 Cr | ₹8 Cr | ₹10 Cr |
| EPS | 3.65 | 3.78 | 3.93 | 1.56 | 0.58 | 0.87 | 1 | 1.22 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹76 Cr | ₹75 Cr | ₹76 Cr | ₹77 Cr | ₹87 Cr | ₹96 Cr | ₹120 Cr | ₹153 Cr |
| Total Liabilities | ₹48 Cr | ₹45 Cr | ₹43 Cr | ₹41 Cr | ₹44 Cr | ₹44 Cr | ₹57 Cr | ₹78 Cr |
| Equity | ₹28 Cr | ₹30 Cr | ₹32 Cr | ₹37 Cr | ₹44 Cr | ₹52 Cr | ₹62 Cr | ₹75 Cr |
| Total Debt | — | — | — | — | — | — | — | ₹19 Cr |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹-10 Cr | ₹8 Cr | ₹11 Cr | ₹6 Cr | ₹9 Cr | ₹6 Cr |
| Investing | ₹-17 Cr | ₹-2 Cr | ₹-7 Cr | ₹-3 Cr | ₹-3 Cr | ₹-5 Cr |
| Financing | ₹18 Cr | ₹-6 Cr | ₹-2 Cr | ₹0 Cr | ₹-1 Cr | ₹-55,00,000 Cr |
| Free Cash Flow | ₹-10 Cr | ₹8 Cr | ₹11 Cr | ₹6 Cr | ₹9 Cr | ₹1 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.
medicoremedies.com ↗As of 2026-03-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.3% | 73.3% | 73.3% | 73.3% | 73.3% | 73.3% | 66.8% | 63.8% | 62.6% | 61.4% | 61.4% | 61.4% |
| FIIs | 1.2% | 1.1% | 1.3% | 0.3% | 0.2% | 0.2% | 0.4% | 0.1% | 0.1% | 0.3% | 0.5% | 0% |
| DIIs | 0% | 0% | 0% | 0.7% | 1% | 1% | 0.8% | 0% | 0% | 0% | 0% | 0% |
| Public | 25.5% | 25.5% | 25.4% | 25.6% | 25.5% | 25.5% | 32% | 36.1% | 37.3% | 38.3% | 38.1% | 38.6% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 5,055 | 5,264 | 6,052 | 10,685 | 12,902 | 12,887 | 14,104 | 15,424 | 16,474 | 18,503 | 16,562 | 16,189 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Haresh Kapurlal Mehta | Shareholding of Promoter and Promoter Group | 20.2% | 1.68 Cr |
| Mehta Rishit Hareshbhai | Shareholding of Promoter and Promoter Group | 12.7% | 1.05 Cr |
| Harshit Haresh Mehta | Shareholding of Promoter and Promoter Group | 10.4% | 86,20,000 |
| Rita H Mehta | Shareholding of Promoter and Promoter Group | 8.1% | 66,78,000 |
| Ravi Goyal | Public Shareholding | 6.8% | 56,64,309 |
| Shweta Harshit Mehta | Shareholding of Promoter and Promoter Group | 5.9% | 48,82,170 |
| Priyal Rishit Mehta | Shareholding of Promoter and Promoter Group | 4.2% | 34,77,775 |
| Metasoni Alloys Pvt Ltd | Public Shareholding | 1.2% | 10,30,700 |
| Haresh K Mehta Huf | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Harshit H Mehta Huf | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Haresh Kapurlal Mehta | 0 | 0% | 2026-03-31 |
| Mehta Rishit Hareshbhai | 0 | 0% | 2026-03-31 |
| Harshit Haresh Mehta | 0 | 0% | 2026-03-31 |
| Rita H Mehta | 0 | 0% | 2026-03-31 |
| Shweta Harshit Mehta | 0 | 0% | 2026-03-31 |
| Priyal Rishit Mehta | 0 | 0% | 2026-03-31 |
| Haresh K Mehta Huf | 0 | 0% | 2026-03-31 |
| Harshit H Mehta Huf | 0 | 0% | 2026-03-31 |
| Metasoni Alloys Pvt Ltd | 0 | 0% | 2026-03-31 |
| Ravi Goyal | 0 | 0% | 2026-03-31 |
| Haresh Kapurlal Mehta | 0 | 0% | 2025-12-31 |
| Mehta Rishit Hareshbhai | 0 | 0% | 2025-12-31 |
| Name | Designation | Year |
|---|---|---|
| Haresh Mehta | Chairman & Executive Director & CFO | 2025 |
| Harshit Mehta | ED / MD / Promoter | 2025 |
| Rishit Mehta | E D & Wholetime Director | 2025 |
| Rita Mehta | Non-Exec & Non-Independent Dir | 2025 |
| Deepak Vekaria | Independent Non Exe. Director | 2025 |
| Bharat Rathod | Independent Non Exe. Director | 2025 |
| Deepesh Rajesh Shah | Independent Non Exe. Director | 2025 |
| Kunal Vora | Independent Non Exe. Director | 2025 |
| Anuj Kishore Mody | Independent Non Exe. Director | 2025 |
| Maheshkumar Darji | Independent Non Exe. Director | 2025 |
| Vidhi Ankit Shah | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Manufacturers of Pharmaceutical For | ₹0 Cr | — |
| Region | Revenue | Share |
|---|---|---|
| India | ₹7 Cr | 13.6% |
| Outside India | ₹45 Cr | 86.4% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹2 | 17 | 17 | 17 |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 4 | 0 | 4 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 2 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 3 |
13 recent disclosure(s)
23 disclosure(s)
📍 1105/1106 11-Flr Hubtown Solar, N S Phadke Marg Andheri East, Mumbai, Maharashtra, 400069
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search